Stem cell exosome treatment for active ulcerative colitis
Part of Digestive system clinical trials.
This study tests whether a new treatment made from stem cell particles (called exosomes) can help calm moderate-to-severe ulcerative colitis when standard medicines haven't worked well enough. The treatment is given directly into the vein or under the skin, and the goal is to reduce symptoms and inflammation in the colon.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have had ulcerative colitis for at least 3 months, with a confirmed diagnosis.
- Your colitis must be moderately to severely active — meaning symptoms like frequent bowel movements, rectal bleeding, and visible inflammation on a colonoscopy.
- You need to be between 18 and 75 years old and weigh at least 40 kg (about 88 lbs).
- You must have tried at least one standard treatment (like mesalamine, steroids, immunosuppressants, or biologics) and it didn't work well enough, or you couldn't tolerate its side effects.
- If you're on certain UC medications (like steroids or mesalamine), you need to be on a stable dose for at least 2 weeks before starting the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug called HSK47388 for people with moderate to severe ulcerative colitis who have not had good results from other treatments. The goal is to see if it can reduce inflammation and improve symptoms.
This trial tests an oral study drug called Hemay005 for people with moderate to severe ulcerative colitis (UC) who have not responded well to other treatments. If you join, you will receive either the study drug or a placebo (inactive pill) to see if it helps reduce symptoms and heal the gut lining.
This study tests a new drug called XmAb942 for people with moderate to severe ulcerative colitis. It aims to see if the drug can reduce inflammation and improve symptoms when other treatments haven't worked well enough or caused side effects.
This study tests whether a combination of fecal transplant (transferring healthy stool into your gut) and dietary changes can help control inflammation in people recently diagnosed with active ulcerative colitis. It may offer a new treatment option before starting stronger medications.
This trial compares two oral medicines — etrasimod (a newer drug that works on the immune system) and mesalazine (a standard anti-inflammatory) — in Chinese adults with active ulcerative colitis. It aims to see which is better at controlling symptoms and is safer. If you have mild to moderate active UC, you may join.
This trial tests whether taking selenium supplements can help people with moderate to severe ulcerative colitis that is being treated with advanced therapies (biologics). The goal is to see if selenium can improve symptoms and reduce inflammation.
Hear when a new Ulcerative Colitis (UC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.